Sagimet Biosciences Stock (NASDAQ:SGMT)

Forecast Revenue Ownership Financials Chart

Previous Close

$3.40

52W Range

$2.13 - $20.71

50D Avg

$3.08

200D Avg

$5.02

Market Cap

$114.11M

Avg Vol (3M)

$434.23K

Beta

-

Div Yield

-

SGMT Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Jul 17, 2023

Website

SGMT Performance

SGMT Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$2.00M	-	-
Operating Income	$-30.74M	$-31.05M	$-23.72M
Net Income	$-27.88M	$-30.50M	$-24.44M
EBITDA	$-30.74M	$-31.05M	$-23.72M
Basic EPS	-	$-1.38	$-1.10
Diluted EPS	-	$-1.38	$-1.10

Fiscal year ends in Dec 23 | Currency in USD